- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05431699
Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test (SCALE)
SCALE: Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test: Efficacy and Cost Effectiveness
Study Overview
Status
Conditions
Detailed Description
Study Design:
Interventional study
Study Procedures:
Enrollment: Given our previous experience24 it will be feasible to enroll 60 women per week to comfortably meet our recruitment goal of 12,000 women in 50 months. MOH community health promoters will provide community outreach and schedule appointments for eligible women. Eligible women who consent will complete a brief intake questionnaire in a private room and be instructed on how to properly perform a self-collection of ScreenFire. After self-collecting the HPV ScreenFire test, women will have a provider-collected careHPV test during a standard speculum exam. All COVID-19 precautions will be carefully followed. To be enrolled, all participants will need to complete both HPV screening methods.
Self-collection of ScreenFireHPV: Participants will be invited to complete HPV primary screening by self-collection on the same day that they attend the clinic. The nurse will provide illustrated instructions about this process (see Figure 2), answer any questions, then show the participant to a private room. Self-samples are collected by gently inserting a sterile dry swab into the vagina until the woman feels resistance, rotating the brush five full 360° turns, withdrawing the swab, placing it into the tube, breaking off the top portion of the swab, and closing and returning the tube to the study nurse. Self-collected dry samples can be stored without preservative at room temperature and are stable for at least 32 weeks.31 Self-collected specimens will be analyzed per manufacturer's instructions with the ScreenFire platform at a local lab. Each participant's HPV test will be recorded as negative or positive, and if positive the specific HPV category(ies) will be recorded and uploaded into the REDCap database. The HPV categories are the following: Group 1 (HPV type 16); Group 2 (HPV types 18 and 45); Group 3 (HPV types 33,31,52,58,35); and Group 4 (HPV types 39,51,59,56,68).
Study Population:
The investigators will enroll 12,000 women from clinics in El Salvador. The ScreenFire PCR machine has been used in El Salvador for COVID testing, and laboratory personnel are already trained on how to correctly run the machine.
Key personnel:
At study start-up, Drs. Cremer and Wang will launch the trial in El Salvador in person, if possible, or virtually if COVID restrictions remain in place. Once the clinical trial begins, the team will have bi-monthly phone calls to discuss study progress and any potential issues.
Study personnel will visit each of the 152 participating clinics. All interviews, consents, and exams will be performed by study staff, with administrative assistance from MOH community health center workers. Samples will be sent to a local laboratory.
Data Collection & Management:
Pathologist readings: Cervical biopsies will be transported study personnel to senior pathologists in San Salvador.36-38 Local pathology results will be used for referral to treatment per standard-of-care guidelines.39 Gynecologic pathologists from the United States will evaluate the slides with CIN2+ diagnoses and a 5% random sample of CIN1/normal pathology slides on a regular basis to ensure quality and for expert confirmation of study endpoints. The evaluation may be done in person or remotely using a slide scanner. It is important to have the pathologists differentiate CIN2 from CIN3 diagnoses, given recent epidemiological evidence that CIN3 is more likely to progress to invasive cervical cancer (ICC).40-42 For disagreement in diagnosis, a third expert pathologist will adjudicate the discrepancy. Pathologists will be blinded to HPV status and to each other's diagnoses.
Analysis Plan:
The primary analysis will evaluate the sensitivity of self-collected ScreenFire versus standard provider-collected careHPV for the detection of high-grade cervical precancer (CIN2+) in HPV+ women. Women who are HPV negative are unlikely to have high-risk precancer, therefore only a subset (5%) of the HPV negative women will be screened with colposcopy and undergo biopsy.3,43 Histology results from those 5% randomly selected HPV negative participants who attend colposcopy (N=475) will allow correction for potential verification bias. Maximum likelihood estimates (MLEs)44 will be used to provide statistically valid estimates of sensitivity and corresponding 95% confidence intervals (CIs). The secondary analysis will involve estimation of the specificity, positive predictive value (PPV), and negative predictive value (NPV) of primary high-risk HPV testing in ScreenFire self-collection vs. careHPV provider-collection for CIN2+ detection using similar MLE estimates as described above. For CIN3+ endpoints, the investigators will assess test performance (sensitivity, specificity, NPV, PPV) for self-collected ScreenFire and provider-collected careHPV as descriptive analyses.
Non-participation documentation:
Demographic characteristics and reasons for ineligibility and/or declining trial participation will be recorded for patients who are asked to participate but do not enroll in the study. Those who decline participation will be invited to fill out the demographic form so data can be gathered on non-participation. Data will be used to evaluate possible selection bias to inform interpretation of study findings.
Statistical power and sample size:
Based on screening 12,000 women, and a 12% estimate of HPV positivity to either ScreenFire HPV in self-collected samples or careHPV in provider-collected samples, the investigators expect 1,440 HPV+ women. Assuming a 90% retention from HPV screening to colposcopy, 1,296 are expected to have colposcopy-directed biopsy results. Based on our previous work with HPV+ women in El Salvador,45 the investigators conservatively estimate 10% CIN2+ prevalence among HPV+ women and 130 CIN2+ cases. There is 80% power to detect a 5% difference in sensitivity of ScreenFire self-collection for CIN2+ detection versus careHPV provider collection (88% vs 93%) at a significance level 0.05. That is, there will be sufficient power to determine that the sensitivity of ScreenFire self-collection for CIN2+ is higher than careHPV provider-collection. There is an 80% power to detect a 4% difference in specificity of ScreenFire self-collection for CIN2+ detection versus careHPV provider-collection (84% vs 88%) at a significance level of 0.05.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miriam Cremer, M.D.
- Phone Number: 216-312-0618
- Email: cremerm@ccf.org
Study Contact Backup
- Name: Carmin M Soler Cruz, Ph.D.
- Phone Number: 347-920-1629
- Email: solerm@ccf.org
Study Locations
-
-
-
San Salvador, El Salvador
- Recruiting
- Ministerio de Salud
-
Contact:
- Karla Alfaro, M.D.
- Phone Number: 503-7854-7746
- Email: kalfaro@basichealth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- Female, aged 30-59
Exclusion Criteria:
- Pregnancy at time of colposcopy/biopsy
- Hysterectomy with surgically absent cervix
- Cervical cancer screening in the past two years
- Prior diagnosis or treatment of invasive cervical cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Screening population
Women eligible for HPV screening will receive both ScreenFire (experimental) and careHPV (active comparator) based on El Salvador's national guidelines.
|
The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings.
It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen.
Electricity is necessary to run the test, but it does not need running water or air conditioning.
In order to be most cost effective, the samples must be run with a full plate of 96 samples.
Results take 3-4 hours to complete.
A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue.
After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV.
Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix).
Tissue specimens are then sent to the lab for pathology diagnosis.
Cryotherapy is performed to treat high-grade cervical precancer.
First, a speculum is introduced into the vagina to identify the cervix.
Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer.
If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix.
Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an "ice ball" on the cervix.
The ice ball ablates or destroys the abnormal cells.
Thermal ablation is utilized to treat high-grade cervical precancer.
First, a speculum is introduced into the vagina to identify the cervix.
Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer.
If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour.
The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types.
The human cellular gene beta-globin is used as an internal control to measure sample adequacy.
ScreenFire can be self-collected and does not require batching.
AmpFire® obtained CE-mark in 2017.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity
Time Frame: 4-years
|
Proportion of true HPV positive cases based on biopsy detected by ScreenFire test via self-collection compared to careHPV via provider collection
|
4-years
|
Lost to follow-up
Time Frame: 6-months
|
Proportion of participants who do not complete their treatment six months after screening.
|
6-months
|
Cost-effectiveness
Time Frame: 4-years
|
Incremental Cost Effectiveness Ratios (ICER) will be reported for each screening strategy as cost per life year saved and cost per DALY (disability-adjusted life years) averted.
|
4-years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity
Time Frame: During specific Aim 1, at baseline visit
|
Proportion of true HPV negative cases based on biopsy detected by ScreenFire test via self-collection compared to careHPV via provider collection
|
During specific Aim 1, at baseline visit
|
Positive predictive value (PPV)
Time Frame: During specific Aim 1, at baseline visit
|
Proportion of participants with ScreenFire positive tests that have cervical precancer based on biopsy compared to those with positive careHPV positive tests
|
During specific Aim 1, at baseline visit
|
Negative predictive value (NPV)
Time Frame: During specific Aim 1, at baseline visit
|
Proportion of participants with ScreenFire negative tests that do not have cervical precancer based on biopsy compared to those with negative careHPV positive tests
|
During specific Aim 1, at baseline visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Miriam Cremer, M.D., The Cleveland Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papilloma Virus
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLCCompletedCervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6United States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
Xiamen Innovax Biotech Co., LtdZhejiang Provincial Center for Disease Control and PreventionActive, not recruitingHuman Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus InfectionChina
-
The Behavioural Insights TeamUNICEF; National Center for Disease Control and Public Health, Georgia; Information...Not yet recruitingHPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
-
Universitair Ziekenhuis BrusselRecruiting
-
Universiti Sains MalaysiaRecruitingHuman Papilloma Virus InfectionMalaysia
-
Universiteit AntwerpenCompletedHuman Papilloma Virus InfectionBelgium
-
Gen-Probe, IncorporatedCompletedHuman Papilloma Virus InfectionUnited States
-
Shanghai Zerun Biotechnology Co.,LtdGuangxi Center for Disease Control and PreventionCompletedCervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
Clinical Trials on careHPV test
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
Guven Health GroupCompletedAthletic Performance | Physical Fitness | Handball Players | Cross-sectional StudiesTurkey
-
French National Agency for Research on AIDS and...Completed
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
University of MichiganCompletedAntidepressants Causing Adverse Effects in Therapeutic UseUnited States
-
University of BaghdadCompletedSexual Behavior | Sexual Orientation Conflict Disorder | Sexual Arousal Disorder | Sexual Orientation | Sexual; Orientation, Relationship DisorderIraq